Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (13535)	8/17/1998 9:31:00 PM
From: VLAD	Respond to of 23519

martin, Here is a link to a message I wrote to the Kahuna on the Pfizer thread assessing Viagra failures: www3.techstocks.com IMO it is vital for Vivus to sign a domestic partner to capitalize on the Viagra failures. As I posted before, based on a current script retention of 4,500 and an average Viagra total IMS script average of 200,000 with a 45% failure rate meaning 90,000 scripts on average failing then if Vivus can capitalize on getting only a small percentage of failures to become MUSE patients they can do very well. I will jot a quick table of translations of MUSE IMS script numbers correlated to % of the 90,000 failures using MUSE % of Viagra failures going to MUSE/Total IMS script translation 5% = 4,500 + 4,500 = 9,000 10%= 9,000 + 4,500 =13,500 15%=13,500 + 4,500 =18,000 beats '97 average of 15,800 20%=18,000 + 4,500 =22,500 25%=22,500 + 4,500 =27,000 30%=27,000 + 4,500 =31,500 at this point we double '97 average Domestic partner, Domestic partner, Domestic partner!